Long-term neurotoxicity of chemotherapy in adolescents and young adults treated for bone and soft tissue sarcomas

Sarcoma

Volumn 2, Issue 2, 1998, Pages 97-105

  Earl, Helena M ^a,d   Connolly, Sean ^b   Latoufis, Christos ^c   Eagle, Karen ^c   Ash, Catherine M ^c   Fowler, Clare ^b   Souhami, Robert L ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Adolescent cancer; Bone and soft tissue sarcomas; Long term cisplatin neurotoxicity

Indexed keywords

CISPLATIN; IFOSFAMIDE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; AUDIOMETRY; AUTONOMIC DYSFUNCTION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEARING LOSS; HUMAN; MALE; NERVE CONDUCTION; NEUROPATHY; NEUROTOXICITY; OSTEOSARCOMA; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; VIBRATION SENSE;

EID: 0031880024     PISSN: 1357714X     EISSN: None     Source Type: Journal    
DOI: 10.1080/13577149878055     Document Type: Article

References (49)

1. Stiller CA, Bunch KJ. Trends in survival for childhood cancer in Britain diagnosed 1971-85. Br J Cancer 1990; 62:806-15.
2. Craft A. Chemotherapy of Ewing's Sarcoma. In: Souhami RL, ed. Bone Tumours. London, Philadelphia, Toronto, Sydney, Tokyo: Bailliere Tindall, 1987: 205-21.
3. Boyer M, Raghavan D, Harris PJ, et al. Lack of late toxicity in patients with cisplatin-containing combination chemotherapy for metastatic testicular cancer. J Clin Oncol 1990; 8:21-6.
4. Daugaard GK, Petrera J, Trojaborg W. Electrophysiological study of the peripheral and central neurotoxic effect of cisplatin. Acta Neurol Scand 1987; 76:86-93.
5. Rosen G, Marcove RC, Huvos AG, et al. Primary osteogenic sarcoma: eight years experience with adjuvant chemotherapy. J Cancer Res Clin Oncol 1983; 106(Suppl): 55-67.
6. Rosen GA. Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma: a ten year experience. Orthopedics 1985; 8:659-64.
7. Earl HM, Pringle J, Kemp H, et al. Chemotherapy of malignant fibrous histiocytoma of bone. Ann Oncol 1993; 4:409-15.
8. Heier MS, Nilsen T, Graver V, et al. Raynaud's phenomenon after combination chemotherapy of testicular cancer measured by laser doppler flowmetry. A pilot study. Br J Cancer 1991; 63:550-2.
9. Fossa SD, Aass N, Ous S, et al. Long-term morbidity and quality of life in testicular cancer patients. Scand J Urol Nephrol 1991; 138:241-6.
10. Nielsen VK. The peripheral nerve function in chronic renal failure, IV. An analysis of the vibration perception threshold. Acta Med Scand 1972; 191:287-96.
11. Fowler CJ, Carroll MB, Burns D, et al. A portable system for measuring cutaneous thresholds for warming and cooling. J Neurol Neurosurg Psychiatry 1987; 50:1211-5.
12. Ewing DJ, Clarke B. Autonomic neuropathy: its diagnosis and prognosis. Clin Endocrinol Metab 1986; 15:855-88.
13. Robinson R. Effect of statistical methodology on normal limits in nerve conduction studies. Muscle Nerve 1991; 14:1084-90.
14. Robinson R, Cantwell BMJ. Autonomic neuropathy after cisplatin based chemotherapy. Br Med J 1990; 300:466-75.
15. Cersosimo RJ. Cisplatin neurotoxicity. Cancer Treat Rev 1989; 6:195-211.
16. van der Hoop RG, van der Burg ME, ten Bokkel-Huinink WW, et al. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer 1990; 66:1697-702.
17. Boogerd W, ten Bokkel Huinink WW, Dalesio O, et al. Cisplatin induced neuropathy: central, peripheral and autonomic nerve involvement. J Neurooncol 1990; 9:255-63.
18. Gregg RW, Molepo JM, Monpetit VJ, et al. Cisplatin neurotoxicity; the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 1992; 10:795-803.
19. Hakes T, Hoskins W, Jones W, et al. Randomised prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin (CAP) in stage III and IV ovarian cancer. Proc Am Soc Clin Oncol 1990; 9:Abstr 606.
20. Sebille A, St-Guily JL, Angelard B, et al. Low prevalence of cisplatin-induced neuropathy after 4-day continuous infusion in head and neck cancer. Cancer 1990; 65:2644-7.
21. Gandara DR, Perez EA, Hoff J, et al. High dose cisplatin: modulation of toxicity. San Diego, CA: Sixth International Symposium on Platinum and other Metal Coordination Compounds in Cancer. 1991: 51.
22. Hainsworth JD, Burnett LS, Jones HW, et al. High dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian cancer. J Clin Oncol 1990; 8:502-8.
23. Cavaletti G, Petruccioli MG, Tredici G, et al. Effects of repeated administration of low dose cisplatin on the rat nervous system. Int J Tissue React, 1991; 13:151-7.
24. Kim HK, Lee KS, Hong YS, et al. Cisplatin-induced peripheral neuropathy in patients with a history of neurologic damage. Proc Am Soc Clin Oncol 1991; 10:Abstr 1224.
25. Ashraf M, Riggs JE, Wearden S, et al. Prospective study of nerve conduction parameters and serum magnesium following cisplatin therapy. Gynaecol Oncol 1990; 37:29-33.
26. Thompson SW, Davis LE, Kornfeld M, et al. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic study. Cancer 1984; 54: 1269-75.
27. Elderson A, van der Hoop RG, Haanstra W, et al. Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicity. J Neurol Sci 1989; 93:167-74.
28. Cowan JD, Kies MS, Roth JL, et al. Nerve conduction studies in patients treated with cis-diamminedichloroplatinum (II): a preliminary report. Cancer Treat Rep 1980; 64:1119-22.
29. Hansen SW, Helweg-Larson S, Trojaborg W. Longterm neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer. J Clin Oncol 1989; 7:1457-61.
30. Cavanagh JB. Sensorimotor neuropathy and cisplatin and adriamycin toxicity. J Neurol Neurosurg Psychiatry 1986; 49:964-5.
31. Tomiwa K, Nolan C, Cavanagh JB. The effects of cisplatin on rat spinal ganglia. A study by light and electron microscopy and by morphometry. Acta Neuropathol 1986; 69:295-308.
32. Walsh TJ, Clark AW, Parhad IM, et al. Neurotoxic effects of cisplatin therapy. Arch Neurol 1982; 39:719-20.
33. Dewar J, Lunt H, Abernethy DA, et al. Cisplatin neuropathy with Lhermitte's sign. J Neurol Neurosurg Psychiatry 1986; 49:96-9.
34. List AF, Kummet KD. Spinal cord toxicity complicating treatment with cisplatin and etoposide. Am J Clin Oncol 1990; 13:256-8.
35. Hansen SW. Autonomic neuropathy after treatment with cisplatin, vinblastine, and bleomycin for germ cell tumours. Br Med J 1990; 300:511-2.
36. Pages M, Pages AM, Bories-Azeau L. Severe sensorimotor neuropathy after cisplatin therapy. J Neurol Neurosurg Psychiatry 1986; 49:333-4.
37. Samuels BL, Vogelzang NJ, Kennedy BJ. Severe vascular toxicity associated with vinblastine, bleomycin and cisplatin chemotherapy. Cancer Chemother Pharmacol 1987; 19:253-6.
38. Mollman JE. Cisplatin Neuropathy. New Engl J Med 1990; 322:126-7.
39. Mollman JE, Glover DJ, Hogan WM, et al. Cisplatin neuropathy risk factors, prognosis, and protection by WR-2721. Cancer 1988; 61:2192-5.
40. Siegal T, Haim N. Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer 1990; 66: 1117-23.
41. Grunberg SM, Sonka S, Stevenson LL, et al. Progressive parasthesias after cessation of therapy with very high dose cisplatin. Cancer Chemother Pharmacol 1989; 25:62-4.
42. Horwich A, Sleijfer D, Fossa S, et al. A trial of carboplatin-based chemotherapy in good prognosis metastatic testicular non-seminoma. Proc Soc Clin Oncol 1994; 13:Abstr 709.
43. Hamers FP, van der Hoop RG, Steerenburg PA, et al. Putative neurotrophic factors in the protection of cisplatin induced peripheral neuropathy in rats. Toxicol Appl Pharmacol 1991; 111:514-22.
44. Pirovano C, Bohm S, di Re F, et al. Clinical and neurophysiological evaluation of peripheral neurotoxicity following high-dose cisplatin with glutathione protection in the treatment of ovarian cancer. Anticancer Res 1990; 10:1426.
45. Muller LJ, Van der Hoop RG, van Delft MCM, et al. Morphological and electrophysiological study of the effects of cisplatin and ORG 2766 on rat spinal ganglion neurons. Cancer Res 1990; 50:2437-42.
46. van der Hoop RG, Vecht CJ, van der Berg MEL, et al. Prevention of cisplatin neurotoxicity with an ACTH (4-9) analogue in patients with ovarian cancer. New Engl J Med 1990; 322:89-94.
47. Raivich G, Kreutzberg G. Nerve growth factor and regeneration of the peripheral nervous system. Clin Neurol Neurosurg 1993; 95 (Suppl):S84-8.
48. Apfel SC, Arezzo JC, Lipson L, et al. Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol 1992; 31: 76-80.
49. Sara VR. The role of insulin-like growth factors in the nervous system. In: Schofield PN, ed. The Insulin-Like Growth Factors. Structure and Biological Functions. Oxford, New York, Tokyo: Oxford University Press, 1992:258-79.